| References: |
In RG2 rat glioma cells, Bromodeoxyuridine induces a progressive, dose-responsive suppression of cancer cell line and cancer stem cell population expansion. In H9 cells and BJ fibroblasts, Bromodeoxyuridine alters the cell cycle profile. BrdU is stably integrated into the DNA, and thus can be used in assessment of cell proliferation and other cell procession. In rat glioma RG2 tumor model, Bromodeoxyuridine (300 mg/kg, i.p. or 0.8 mg/ml, p.o.) significantly slows tumor progression. [ For the detailed information of Bromodeoxyuridine (BrdU), the solubility of Bromodeoxyuridine (BrdU) in water, the solubility of Bromodeoxyuridine (BrdU) in DMSO, the solubility of Bromodeoxyuridine (BrdU) in PBS buffer, the animal experiment (test) of Bromodeoxyuridine (BrdU), the cell expriment (test) of Bromodeoxyuridine (BrdU), the in vivo, in vitro and clinical trial test of Bromodeoxyuridine (BrdU), the EC50, IC50,and affinity,of Bromodeoxyuridine (BrdU), For the detailed information of Bromodeoxyuridine (BrdU), the solubility of Bromodeoxyuridine (BrdU) in water, the solubility of Bromodeoxyuridine (BrdU) in DMSO, the solubility of Bromodeoxyuridine (BrdU) in PBS buffer, the animal experiment (test) of Bromodeoxyuridine (BrdU), the cell expriment (test) of Bromodeoxyuridine (BrdU), the in vivo, in vitro and clinical trial test of Bromodeoxyuridine (BrdU), the EC50, IC50,and affinity,of Bromodeoxyuridine (BrdU), Please contact DC Chemicals. |
